Preclinical studies show FGF23 inhibition improves erythropoiesis and iron metabolism [91], and phosphate control may reduce FGF23 and improve anemia [92,93], though balancing mineral homeostasis remains challenging [94]. The gene discussed is FGF23; the disease is anemia (phenotype).